The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
The stock, which enjoys the unusual position of having all buy ratings from the 13 analysts offering coverage on FactSet, has been on a tear this year, gaining 270% to date in 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback